Martin Anthony R, Ronco Cyril, Demange Luc, Benhida Rachid
Université Côte d'Azur , CNRS , Institut de Chimie de Nice UMR 7272 - 06108 Nice , France . Email:
UFR des Sciences Pharmaceutiques , Université Paris Descartes , Sorbonne Paris Cité , 4 avenue de l'Observatoire , Paris Fr-75006 , France.
Medchemcomm. 2016 Oct 19;8(1):21-52. doi: 10.1039/c6md00432f. eCollection 2017 Jan 1.
In cancers, hypoxia inducible factor 1 (HIF-1) is an over-expressed transcription factor, which regulates a large set of genes involved in tumour vascularization, metastases, and cancer stem cells (CSCs) formation and self-renewal. This protein has been identified as a relevant target in oncology and several HIF-1 modulators are now marketed or in advanced clinical trials. The purpose of this review is to summarize the advances in the understanding of its regulation and its inhibition, from the medicinal chemist point of view. To this end, we selected in the recent literature relevant examples of "hit" compounds, including small-sized organic molecules, pseudopeptides and nano-drugs, exhibiting and/or both anti-HIF-1 and anti-tumour activities. Whenever possible, a particular emphasis has been dedicated to compounds that selectively target CSCs.
在癌症中,缺氧诱导因子1(HIF-1)是一种过度表达的转录因子,它调控大量参与肿瘤血管生成、转移以及癌症干细胞(CSCs)形成和自我更新的基因。这种蛋白质已被确定为肿瘤学中的一个相关靶点,目前有几种HIF-1调节剂已上市或正处于晚期临床试验阶段。本综述的目的是从药物化学家的角度总结在理解其调控和抑制方面所取得的进展。为此,我们在最近的文献中挑选了“命中”化合物的相关实例,包括小分子有机化合物、拟肽和纳米药物,它们展现出抗HIF-1和抗肿瘤活性中的一种及两种活性。只要有可能,我们就特别关注那些选择性靶向癌症干细胞的化合物。